Skip to main content

Table 2 Intravenous glycoprotein IIb/IIIa receptor blockers for patients undergoing percutaneous coronary intervention

From: Antiplatelet and anticoagulant therapy in elective percutaneous coronary intervention

   

Primary end point

 

Trial

Patient category

n

IIb/IIIa

Placebo

P value

EPIC [72]

AMI, UA or high-risk lesion

2099

8.3

12.8

0.008

EPILOG [74]

SA

2792

5.2

11.7

< 0.001

CAPTURE [62]

Refractory UA

1265

11.3

15.9

0.01

IMPACT-II [77]

AMI, SA,UA

4010

9.2

11.4

0.06

RESTORE [78]

UA

2139

10.3

12.2

0.16

EPISTENT [103]

AMI, UA, SA and stent eligible

2399

5.3

10.8

< 0.001

  1. See text for details of patient selection, primary end points, and outcome. In the EPIC, EPILOG, CAPTURE and EPISTENT trials, the primary end point consisted of death, acute myocardial infarction (AMI) or target vessel revascularization (TVR) at 30 days. In the IMPACT-II trial, the need for a bailout stent also included a primary end point. In the RESTORE trial, not only TVR was included, but any revascularizations. UA, Unstable angina; SA, stable angina.
Back to article page

Trials

ISSN: 1745-6215